Treatment outcome of postoperative radiotherapy for retroperitoneal sarcoma.
10.3857/roj.2011.29.4.260
- Author:
Hyun Jin LEE
;
Si Yeol SONG
;
Tae Won KWON
;
Jeong Hwan YOOK
;
Song Cheol KIM
;
Duck Jong HAN
;
Choung Soo KIM
;
Hanjong AHN
;
Heung Moon CHANG
;
Jin Hee AHN
;
Eun Jin JWA
;
Sang Wook LEE
;
Jong Hoon KIM
;
Eun Kyung CHOI
;
Seong Soo SHIN
;
Seung Do AHN
- Publication Type:Original Article
- Keywords:
Sarcoma;
Retroperitoneal;
Radiotherapy;
Postoperative;
Outcome
- MeSH:
Disease-Free Survival;
Follow-Up Studies;
Humans;
Neoplasm Metastasis;
Prognosis;
Recurrence;
Sarcoma;
Treatment Outcome
- From:Radiation Oncology Journal
2011;29(4):260-268
- CountryRepublic of Korea
- Language:English
-
Abstract:
PURPOSE: To evaluate the treatment outcome and prognostic factor after postoperative radiotherapy in retroperitoneal sarcoma. MATERIALS AND METHODS: Forty patients were treated with surgical resection and postoperative radiotherapy for retroperitoneal sarcoma from August 1990 to August 2008. Treatment volume was judged by the location of initial tumor and surgical field, and 45-50 Gy of radiation was basically delivered and additional dose was considered to the high-risk area. RESULTS: The median follow-up period was 41.4 months (range, 3.9 to 140.6 months). The 5-year overall survival (OS) was 51.8% and disease free survival was 31.5%. The 5-year locoregional recurrence free survival was 61.9% and distant metastasis free survival was 50.6%. In univariate analysis, histologic type (p = 0.006) was the strongest prognostic factor for the OS and histologic grade (p = 0.044) or resection margin (p = 0.032) had also effect on the OS. Histologic type (p = 0.004) was unique significant prognostic factor for the actuarial local control. CONCLUSION: Retroperitoneal sarcoma still remains as a poor prognostic disease despite the combined modality treatment including surgery and postoperative radiotherapy. Selective dose-escalation of radiotherapy or combination of effective chemotherapeutic agent must be considered to improve the treatment result especially for the histopathologic type showing poor prognosis.
